Cargando…

Role of LOXL2 in the epithelial-mesenchymal transition and colorectal cancer metastasis

Colorectal cancer (CRC) is one of the most dangerous types of malignant tumors, and cancer metastasis is a major factor in the failure of CRC therapy. Recently, LOXL2 (lysyl oxidase-like 2) has been shown to represent a regulator of epithelial-mesenchymal transition (EMT) in different cancer types....

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Pil-Gu, Jo, Su Ji, Kim, Min Jung, Kim, Hyun Jeong, Lee, Ji Hae, Park, Cheol Keun, Kim, Hyunki, Lee, Kang Young, Kim, Hoguen, Park, Jeon Han, Dong, Seung Myung, Lee, Jae Myun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655201/
https://www.ncbi.nlm.nih.gov/pubmed/29113306
http://dx.doi.org/10.18632/oncotarget.18170
Descripción
Sumario:Colorectal cancer (CRC) is one of the most dangerous types of malignant tumors, and cancer metastasis is a major factor in the failure of CRC therapy. Recently, LOXL2 (lysyl oxidase-like 2) has been shown to represent a regulator of epithelial-mesenchymal transition (EMT) in different cancer types. However, LOXL2 has not been reported to be involved in CRC metastasis. In this study, we demonstrated that LOXL2 expression is strongly correlated with the rate of CRC metastasis, it participates in the regulation of EMT-related molecule expression in CRC cells in vitro, and it is involved in migratory potential alterations. Additionally, tissue microarray analysis of CRC patients showed an increase in the probability of developing CRC distant metastasis and a decrease in the survival rate of patients with high LOXL2 expression. The results obtained in this study indicate that LOXL2 is involved in the development and progression of CRC metastasis, and therefore, its expression levels may represent a useful prognostic marker.